论文部分内容阅读
去年11月中,堪萨斯威奇塔5名新确诊的糖尿病患者,首次应用由DNA重组方法引入人胰岛素基因的细菌而发生成的胰岛素以进行治疗。 这种重组生成的胰岛素,又称生物合成胰岛素。曾经美、英、希腊、西德的健康自愿者试用过,均未发现毒副作用。此种产品现正在威奇塔的堪萨斯大学医科学院儿科系主任R·格思里教授与新泽西洲特伦顿Mercer医学中心的A.Krosnick医学博士以及美国糖尿病学会前主席和底特律Henrz Ford医院的F.Whitehouse医学博士等监督下进行Ⅱ期试验。每个研究中心要治疗患者50例。
In mid-November last year, five newly diagnosed diabetic patients in Wichita, Kansas, were the first to apply insulin produced by bacteria introduced into the human insulin gene by DNA recombination. This recombinant generated insulin, also known as biosynthetic insulin. Once the United States, Britain, Greece, West Germany, the health volunteers tried before, no side effects were found. Such products are now being presented to Dr. R. Guthrie, the Department of Pediatrics, University of Kansas School of Medicine in Wichita, and Dr. A. Krosnick, MD, of Mercer Medical Center, Trenton, NJ, as well as the former chairman of the American Diabetes Association and the Foster Hospital of Henderson, Detroit .Whitehouse MD and other supervision under phase II trial. Each study center to treat patients in 50 cases.